PT-141

Overview

PT-141 (Bremelanotide) is a synthetic peptide analog of the melanocortin receptor agonist class, derived from α-melanocyte-stimulating hormone (α-MSH). It is studied exclusively in controlled laboratory and preclinical environments for its effects on melanocortin receptor binding, signal transduction, and neuropeptide-related cellular pathways. Research focuses on PT-141’s interaction with MC3R and MC4R receptors and its influence on intracellular signaling and molecular modulation in non-human experimental systems.

Specifications

• Unit Size: 10 mg per vial

• Form: Lyophilized powder

• Storage: Store dry at 2 °C–8 °C. After reconstitution, refrigerate at 2 °C–8 °C and use within 10–14 days.

• Documentation: Certificate of Analysis (COA) and Material Safety Data Sheet (MSDS) available upon request.

Research Context

In vitro and preclinical studies have investigated PT-141 in relation to:

• Melanocortin receptor (MC3R/MC4R) activation and signaling cascade models

• Intracellular cAMP regulation and peptide-mediated receptor binding

• Exploration of hypothalamic and neuroendocrine signaling mechanisms in laboratory settings

• Molecular structure–activity relationships of melanocortin analogs

All data and descriptions are based solely on laboratory and non-human research. No clinical safety or efficacy is implied or established.

Intended Use / Restrictions

• For laboratory research use only

• Not for human or veterinary use

• Not a drug, dietary supplement, or medical device

• Buyer must be a qualified researcher or institution and assumes full responsibility for compliance with institutional and regulatory handling standards.

Important Notice

This material is intended strictly for scientific and educational purposes. No claims are made regarding its safety, therapeutic potential, or suitability for any clinical application. PT-141 is not approved for human or veterinary use. All handling and disposal should follow institutional biosafety procedures.